Journal News

JBC: Scanning thousands of molecules against an elusive cancer target

Sasha Mushegian
Feb. 1, 2019

Researchers at the National Center for Advancing Translational Sciences, or NCATS, part of the National Institutes of Health, have developed a system to accelerate the discovery of chemical compounds that inhibit an enzyme implicated in a number of cancers. The tools and methods the researchers used to test more than 16,000 compounds are described in a paper published in the Journal of Biological Chemistry.

NSD2 screeningA new study developed a set of methods to screen thousands of small molecules to find inhibitors of the cancer target NSD2.Matthew Hall/NCATS

The enzyme, NSD2, is overactive in cancers such as acute lymphoblastic leukemia and certain types of multiple myeloma, so inhibiting NSD2 activity seems like a promising strategy for treating those conditions. But so far researchers have not been able to find any chemicals that reliably block NSD2 even in a test tube in the laboratory, much less to test as drug candidates in living models.

“There’s a total lack of available chemical probes, druglike molecules, to help study (NSD2) function,” said Matthew Hall, the NCATS scientist who oversaw the new work.

It’s been difficult to discover chemical inhibitors of NSD2, in part, because the enzyme is difficult to work with in the laboratory. NSD2 modifies histones, the proteins around which DNA is wound. For technical reasons, scientists ordinarily would study this kind of activity using a fragment of the enzyme and a fragment of histone protein. But NSD2 works on only whole nucleosomes: units of histone protein in combination with DNA.

“(NSD2 and similar proteins) are very picky, because they prefer to only act on whole nucleosomes,” Hall said. “They’re snobby when it comes to what they’re willing to interact with.”

Collaborating with the biotechnology company Reaction Biology, Hall’s team, including lead author Nathan Coussens, developed laboratory tests involving whole nucleosomes that could be used to see whether NSD2 was able to modify histone proteins in the presence of various compounds. The compounds the team tested came from NCATS’s massive library of bioactive chemicals.

But finding a compound that appears to block NSD2 activity is only the beginning. To confirm that the chemicals identified in the initial massive screen were indeed bona fide inhibitors that would reliably and reproducibly perform this function in future researchers’ studies, the NCATS team needed to use multiple types of biochemical methods to confirm the activity of each compound.

“We screened 16,000 molecules, and we got 174 hits, but that doesn’t mean they all really work,” Hall said. “When we whittle away through the (additional screening methods), we get down to 44 molecules. You triage candidates out of your screen after you rigorously ask your molecule to prove itself to you.”

With several molecules now having proved themselves in this round of screening, Hall’s team hopes to continue the search for reliable NSD2 inhibitors that can be used as research tools and then, further down the road, possibly as medicines.

“We are in the process of planning to screen hundreds of thousands of molecules,” Hall said, “in order to find molecules that can be optimized for inhibition of NSD2 and disseminate these to the research community.”

Enjoy reading ASBMB Today?

Become a member to receive the print edition four times a year and the digital edition monthly.

Learn more
Sasha Mushegian

Sasha Mushegian is a postdoctoral fellow at Georgetown University. Follow her on Twitter.

Get the latest from ASBMB Today

Enter your email address, and we’ll send you a weekly email with recent articles, interviews and more.

Latest in Science

Science highlights or most popular articles

Receptor antagonist reduces age-related bone loss in mice
Journal News

Receptor antagonist reduces age-related bone loss in mice

Aug. 6, 2025

Receptor antagonist reduces bone loss and promotes osteoblast activity in aging mice, highlighting its potential to treat osteoporosis. Read more about this recent JBC paper.

Engineered fusion protein targets kiwifruit pathogen
Journal News

Engineered fusion protein targets kiwifruit pathogen

Aug. 6, 2025

Synthetic protein selectively kills kiwifruit pathogen, offering a promising biocontrol strategy for agriculture. Read more about this recent JBC paper.

Pathogen-derived enzyme engineered for antibiotic design
Journal News

Pathogen-derived enzyme engineered for antibiotic design

Aug. 6, 2025

Engineered variants of a bacterial enzyme developed at the University at Buffalo accept larger substrates, paving the way for new acinetobactin-based antimicrobials. Read more about this recent JBC paper.

Omega-3 fats linked to healthy aging and improved heart metabolism
Journal News

Omega-3 fats linked to healthy aging and improved heart metabolism

Aug. 1, 2025

Scientists from the University of Iowa find that a diet high in polyunsaturated fatty acids from fish oil increases cardiac triglyceride uptake and improves insulin sensitivity. Read more about this recent JLR study.

RA patient blood reveals joint innerworkings
Journal News

RA patient blood reveals joint innerworkings

July 25, 2025

Researchers in the Netherlands use mass spectrometry to compare the proteome of plasma and synovial fluid in rheumatoid arthritis patients and find a correlation. Read more about this recent paper in Molecular & Cellular Proteomics.

Hope for a cure hangs on research
Essay

Hope for a cure hangs on research

July 17, 2025

Amid drastic proposed cuts to biomedical research, rare disease families like Hailey Adkisson’s fight for survival and hope. Without funding, science can’t “catch up” to help the patients who need it most.